Your browser doesn't support javascript.
loading
Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith, Chevaun D; Knox, Tatiana M; Filic, Ivona; Soroko, Kara M; Eschle, Benjamin K; Wilkens, Margaret K; Gokhale, Prafulla C; Giles, Francis; Griffin, Andrew; Brown, Bill; Shapiro, Geoffrey I; Zucconi, Beth E; Cole, Philip A; Lemieux, Madeleine E; French, Christopher A.
Afiliación
  • Morrison-Smith CD; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Knox TM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Filic I; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Eschle BK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Giles F; Developmental Therapeutics Consortium, Chicago, Ilinois.
  • Griffin A; Praxis Precision Medicines, Cambridge, Massachusetts.
  • Brown B; Paraza Pharma Inc., Montreal, Quebec, Canada.
  • Shapiro GI; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Zucconi BE; Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Cole PA; Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
  • Lemieux ME; Bioinfo, Plantagenet, Ontario, Canada.
  • French CA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. cfrench@bwh.harvard.edu.
Mol Cancer Ther ; 19(7): 1406-1414, 2020 07.
Article en En | MEDLINE | ID: mdl-32371576
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridonas / Factores de Transcripción / Bencimidazoles / Proteínas Nucleares / Carcinoma / Regulación Neoplásica de la Expresión Génica / Proteínas de Ciclo Celular / Proteína p300 Asociada a E1A / Proteínas de Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridonas / Factores de Transcripción / Bencimidazoles / Proteínas Nucleares / Carcinoma / Regulación Neoplásica de la Expresión Génica / Proteínas de Ciclo Celular / Proteína p300 Asociada a E1A / Proteínas de Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos